Rejuvel Bio-Sciences, Inc. booked $70.4k in FY2014 revenue, contracting 25% year over year — slower than 84% of Consumer Defensive companies we track, at a -348.0% net margin.
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.